The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
Formula attenuates 99% of 365 coronaviruses in computer models
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
The business is a recognized leader in managing Covid-19 and mRNA research programs
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
Subscribe To Our Newsletter & Stay Updated
